Liraglutide Evidence Guide
Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound.
Our Take
Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound.
- Evidence context
- Obesity, type 2 diabetes, weight management research, GLP-1 reference compound
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 0.6mg subcutaneous daily, titrating to 3mg over 5 weeks (Saxenda dosing)
Benefits and Evidence
- Weight Loss: Level A, includes human evidence - SCALE trials demonstrated ~8% weight loss with 3.0mg daily dose. Less weight loss than semaglutide but well-established efficacy and safety profile.
- Blood Sugar Control: Level A, includes human evidence - Extensive clinical data supporting HbA1c reduction. LEAD trial program demonstrated superiority over several diabetes medications.
- Cardiovascular Protection: Level A, includes human evidence - LEADER trial showed 13% reduction in major adverse cardiovascular events. First GLP-1 to demonstrate CV benefits in a dedicated outcomes trial.
Side Effects and Warnings
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Headache
- Injection site reactions
- Boxed warning: thyroid C-cell tumors in rodents
- Pancreatitis risk
Research Dosage References
- <strong>Subcutaneous (diabetes)</strong> - 0.6-1.8 mg - Once daily - Start 0.6mg for one week, increase to 1.2mg, max 1.8mg (Victoza).
- <strong>Subcutaneous (weight)</strong> - 0.6-3.0 mg - Once daily - Gradual escalation over 5 weeks to target 3.0mg dose (Saxenda).
Mechanism of Action
Liraglutide shares the GLP-1 mechanism: 1. GLP-1 receptor activation: Binds to and activates GLP-1 receptors throughout the body. 2. Appetite suppression: Central appetite regulation through hypothalamic GLP-1 receptors. 3. Insulin secretion: Glucose-dependent insulin stimulation from pancreatic beta cells. 4. Glucagon reduction: Suppresses inappropriate glucagon secretion. 5. Gastric slowing: Delays gastric emptying, contributing to satiety and glycemic control.
Legal Status
FDA-approved for type 2 diabetes (Victoza, 2010) and chronic weight management (Saxenda, 2014). Prescription required. Widely available globally.
Primary Sources
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). N Engl J Med, 2016.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). N Engl J Med, 2015.
Quick Answers
Where is the strongest evidence for Liraglutide?
Liraglutide is FDA-approved for type 2 diabetes (Victoza) and obesity (Saxenda), with Phase 3 RCT data (SCALE trial) showing 8-9% body weight reduction - meaningful but less than semaglutide or tirzepatide. It is well-characterized with a long safety record. For weight management research where once-daily dosing is acceptable, liraglutide is a solid, established reference compound. Evidence context: Obesity, type 2 diabetes, weight management research, GLP-1 reference compound.
What are the main side effects of Liraglutide?
Liraglutide side effects and warning signals include Nausea, Vomiting, Diarrhea, Constipation, and Headache.
What evidence level is Liraglutide?
Liraglutide is rated Level A; the listed research status is FDA Approved.